OPC-28326

DB05461ExperimentalSmall molecule

At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary,... It is the only clinical compound with this profile.

Mechanism: At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2C-adrenoceptors. Other studies have also reported selectivity for a-2B-adrenoceptors.
Curator reviewed
Primary indication: Investigated for use/treatment in peripheral vascular disease and raynaud's disease.Curator reviewed
Formula / weight: C₂₆H₃₈ClN₃O₃ · 476.051 g/mol (avg)
Code names: OPC-28326

Resolves to

Compound

UNIIFR0M0E7AZMPubChem15942713

Structure

InChIKeyQRNMKZJPTYRAIL-UHFFFAOYSA-NSMILESO.Cl.CCC(=O)NC1=C(C)C=C(C=C1C)C(=O)N1CCC(CC1)N(C)CCC1=CC=CC=C1

Targets

P25100ADRA1DP41595HTR2BP18825ADRA2CP18089ADRA2B

What you can answer from here — as of April 02, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with OPC-28326, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account